Novozymes A/S
Novozymes A/S operates in the Materials sector, specifically within the Chemicals industry, generating revenue through its core chemical activities.
Business. Novozymes A/S (NVZMY.O) is a Danish company operating in the chemicals industry within the materials sector. The firm is headquartered in Denmark and is listed on the NASDAQ exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
- Congressional trades
- CongressJosh Gottheimer — Novozymes A/S Unsponsored2023-10-16 · Democrat · NJ · Purchase · $1,001 - $15,000
- CongressJosh Gottheimer — Novozymes A/S Unsponsored2023-09-15 · Democrat · NJ · Sale · $1,001 - $15,000
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Novozymes A/S (NVZMY.O) is a Danish company operating in the chemicals industry within the materials sector. The firm is headquartered in Denmark and is listed on the NASDAQ exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.
Novozymes A/S maintains a capital structure characterized by a debt-to-equity ratio of 0.28 and a current ratio of 0.72. The balance sheet reflects total assets of 16.35 billion EUR against total liabilities of 5.49 billion EUR, resulting in total equity of 10.86 billion EUR. Long-term debt stands at 3.01 billion EUR, while cash and equivalents are limited to 275.3 million EUR. This results in a negative net cash position, as total debt exceeds liquid assets. The company generates operating cash flow of 1.22 billion EUR, but free cash flow is constrained to 284.9 million EUR due to capital expenditures of 470.8 million EUR.
Profitability metrics indicate a return on equity of 5.38% and a return on assets of 3.57%. The company reports a gross profit of 2.24 billion EUR on revenue of 4.16 billion EUR, yielding an operating income of 816.7 million EUR and net income of 583.6 million EUR. The valuation multiples reflect a price-to-earnings ratio of 43.44, a price-to-book ratio of 2.34, and an EV/EBITDA of 34.38. The EV/Revenue multiple is 6.75. These returns and multiples must be viewed in the context of the broader Chemicals industry, though specific cohort median comparisons are not provided in the current data set.
Revenue concentration and geographic exposure details are not explicitly broken down in the available segment or geography sections. The company’s activity is broadly defined as Chemicals within the Materials sector. Without specific segment revenue data, the analysis relies on the aggregate financial performance of the entire entity. The lack of granular segment data limits the ability to assess specific growth drivers or regional risks within the portfolio.
Growth trajectory analysis is constrained by the absence of historical period data in the input. The current financial snapshot provides a single-period view of revenue at 4.16 billion EUR and net income at 583.6 million EUR. Without multi-year annual or quarterly trends, it is not possible to calculate year-over-year growth rates or assess the consistency of revenue expansion. The analysis therefore focuses on the current period's absolute performance and valuation metrics.
Risk assessment indicates medium liquidity risk and low dilution risk. A key flag notes that net cash is negative after subtracting total debt, highlighting a reliance on debt financing relative to liquid reserves. The current ratio of 0.72 suggests potential short-term liquidity pressure, as current liabilities exceed current assets. However, the low dilution risk implies that share count stability is maintained, with basic and diluted shares outstanding both at 412.5 million.
Recent observations include a market capitalization reference of approximately 25.44 billion USD and a workforce of 11,641 employees as of 2025-12-31. The company is headquartered in Denmark and was incorporated on 2000-11-13. ESG pillar scores indicate a controversies score of 100, governance of 36, and social of 75. News event observations contain technical failure logs related to data processing ("failed_redrive") rather than substantive corporate events, indicating no significant recent public disclosures or news triggers in the provided data.
- Novozymes trades at a high P/E of 43.44 and EV/EBITDA of 34.38, suggesting premium valuation expectations.
- Liquidity is constrained with a current ratio of 0.72 and negative net cash position due to 3.01 billion EUR in long-term debt.
- Profitability is modest with ROE of 5.38% and ROA of 3.57%, driven by 583.6 million EUR net income on 4.16 billion EUR revenue.
- Free cash flow is limited to 284.9 million EUR after 470.8 million EUR in capital expenditures.
- Dilution risk is low with stable share count, but liquidity risk is medium due to short-term coverage ratios.
- No historical growth data or segment breakdowns are available to assess trend consistency or revenue concentration.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Reference data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Price To Tangible Bookmarket_price / (tangible_book_value / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Return On Equitynet_income / total_equity
- Enterprise Valuemarket_cap - net_cash
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Novozymes A/S Market data — financials · 2026-07-28
- failed_redrive (failed_redrive) on NVZMY.O · 2026-07-28
- Novozymes A/S — company reference export (2026-07-05) · 2026-07-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M